148 related articles for article (PubMed ID: 23241276)
1. Current status of health technology reassessment of non-drug technologies: survey and key informant interviews.
Leggett LE; Mackean G; Noseworthy TW; Sutherland L; Clement F
Health Res Policy Syst; 2012 Dec; 10():38. PubMed ID: 23241276
[TBL] [Abstract][Full Text] [Related]
2. Health technology reassessment of non-drug technologies: current practices.
Leggett L; Noseworthy TW; Zarrabi M; Lorenzetti D; Sutherland LR; Clement FM
Int J Technol Assess Health Care; 2012 Jul; 28(3):220-7. PubMed ID: 22980697
[TBL] [Abstract][Full Text] [Related]
3. Health technology reassessment: the art of the possible.
MacKean G; Noseworthy T; Elshaug AG; Leggett L; Littlejohns P; Berezanski J; Clement F
Int J Technol Assess Health Care; 2013 Oct; 29(4):418-23. PubMed ID: 24290335
[TBL] [Abstract][Full Text] [Related]
4. A systematic review on current status of health technology reassessment: insights for South Korea.
Seo HJ; Park JJ; Lee SH
Health Res Policy Syst; 2016 Nov; 14(1):82. PubMed ID: 27835964
[TBL] [Abstract][Full Text] [Related]
5. Sustainability of healthcare systems in Asia: exploring the roles of horizon scanning and reassessment in the health technology assessment landscape.
Mundy L; Trowman R; Kearney B
Int J Technol Assess Health Care; 2020 Jun; 36(3):262-269. PubMed ID: 32389130
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of knowledge translation theories, models and frameworks for health technology reassessment: expert perspectives through a qualitative exploration.
Esmail R; Clement FM; Holroyd-Leduc J; Niven DJ; Hanson HM
BMC Health Serv Res; 2021 Apr; 21(1):401. PubMed ID: 33926430
[TBL] [Abstract][Full Text] [Related]
7. Identification of knowledge translation theories, models or frameworks suitable for health technology reassessment: a survey of international experts.
Esmail R; Hanson HM; Holroyd-Leduc J; Niven DJ; Clement FM
BMJ Open; 2021 Jun; 11(6):e042251. PubMed ID: 34158291
[TBL] [Abstract][Full Text] [Related]
8. Knowledge translation and health technology reassessment: identifying synergy.
Esmail R; Hanson H; Holroyd-Leduc J; Niven DJ; Clement F
BMC Health Serv Res; 2018 Aug; 18(1):674. PubMed ID: 30165846
[TBL] [Abstract][Full Text] [Related]
9. Moving low value care lists into action: prioritizing candidate health technologies for reassessment using administrative data.
Soril LJJ; Seixas BV; Mitton C; Bryan S; Clement FM
BMC Health Serv Res; 2018 Aug; 18(1):640. PubMed ID: 30111308
[TBL] [Abstract][Full Text] [Related]
10. UNTANGLING, UNBUNDLING, AND MOVING FORWARD: FRAMING HEALTH TECHNOLOGY REASSESSMENT IN THE CHANGING CONCEPTUAL LANDSCAPE.
Soril LJJ; Niven DJ; Esmail R; Noseworthy TW; Clement FM
Int J Technol Assess Health Care; 2018 Jan; 34(2):212-217. PubMed ID: 29616604
[TBL] [Abstract][Full Text] [Related]
11. Developing a How-to-Guide for Health Technology Reassessment: "The HTR Playbook".
Soril LJJ; Elshaug AG; Esmail R; Chalkidou K; Gad M; Clement FM
Int J Health Policy Manag; 2022 Dec; 11(11):2525-2532. PubMed ID: 35065545
[TBL] [Abstract][Full Text] [Related]
12. Deliberative process of health technology reassessment by health technology assessment agency in Korea.
Shin S; Kim Y; Choi J; Park JY;
Int J Technol Assess Health Care; 2024 May; 40(1):e28. PubMed ID: 38738417
[TBL] [Abstract][Full Text] [Related]
13. Scanning the horizon of obsolete technologies: possible sources for their identification.
Ibargoyen-Roteta N; Gutierrez-Ibarluzea I; Asua J; Benguria-Arrate G; Galnares-Cordero L
Int J Technol Assess Health Care; 2009 Jul; 25(3):249-54. PubMed ID: 19619342
[TBL] [Abstract][Full Text] [Related]
14. Health Technology Agency insights: informing modification of a qualitative benefit risk framework for Health Technology Reassessment of prescription medications.
Maloney MA; Schwartz L; O'Reilly D; Levine M
Int J Technol Assess Health Care; 2019; 35(5):384-392. PubMed ID: 31524113
[TBL] [Abstract][Full Text] [Related]
15. Health technology reassessment in the Brazilian public health system: Analysis of the current status.
Pereira VC; Barreto JOM; Neves FADR
PLoS One; 2019; 14(7):e0220131. PubMed ID: 31356609
[TBL] [Abstract][Full Text] [Related]
16. Bioethics, health technology reassessment, and management.
Soril LJ; Clement FM; Noseworthy TW
Healthc Manage Forum; 2016 Nov; 29(6):275-278. PubMed ID: 27744278
[TBL] [Abstract][Full Text] [Related]
17. DISINVESTING FROM INEFFECTIVE TECHNOLOGIES: LESSONS LEARNED FROM CURRENT PROGRAMS.
Mayer J; Nachtnebel A
Int J Technol Assess Health Care; 2015; 31(6):355-62. PubMed ID: 26694654
[TBL] [Abstract][Full Text] [Related]
18. DRUG DISINVESTMENT FRAMEWORKS: COMPONENTS, CHALLENGES, AND SOLUTIONS.
Maloney MA; Schwartz L; O'Reilly D; Levine M
Int J Technol Assess Health Care; 2017 Jan; 33(2):261-269. PubMed ID: 28703087
[TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
20. Development of the International Network of Agencies for Health Technology Assessment.
Hailey D
Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():24-7. PubMed ID: 19500434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
